Table of Content

1. Research Methodology


2. Global Lymphoma Antibody Therapeutics Market
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity


3. Lymphoma Antibody Drug Conjugates - Availability, Dosage, Patent, & Price Analysis
3.1 Brentuximab Vedotin (Adcetris)
3.2 Polatuzumab vedotin (Polivy)
3.3 Loncastuximab Tesirine (Zynlonta)


4. Lymphoma Monoclonal Antibodies - Availability, Patent, Price & Dosage Analysis
4.1 Nivolumab (Opdivo)
4.2 Tafasitamab (Monjuvi/Minjuvi)
4.3 Rituximab (Mabthera/Rituxan)
4.4 Rituximab Biosimilar (Truxima)
4.5 Rituximab Biosimilar (Riabni)
4.6 Rituximab Biosimilar (Ruxience)
4.7 Rituximab/Hyaluronidase (Rituxan Hycela)
4.8 Obinutuzumab (Gazyva)
4.9 Pembrolizumab (Keytruda )
4.10 Sintilimab (Tyvyt)
4.11 Camrelizumab (AiRuiKa)
4.12 Tislelizumab (Baize’an)
4.13 Zimberelimab
4.14 Penpulimab


5. Lymphoma Antibody Drug Conjugates – Global & Regional Sales Analysis
5.1 Adcetris
5.2 Polivy
5.3 Zynlonta


6. Lymphoma Monoclonal Antibodies - Global & Regional Sales Analysis
6.1 Opdivo
6.2 Monjuvi
6.3 Rituxan
6.4 Gazvya
6.5 Keytruda


7. Global Lymphoma Antibodies Clinical Trials Overview
7.1 By Company
7.2 By Country
7.3 By Phase
7.4 By Patient Segment


8. Global Lymphoma Antibodies Clinical Trials By Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
8.9 Registered


9. Marketed Lymphoma Antibodies Clinical Insight by Company, Country & Indication


10. Competitive Landscape
10.1 AbbVie
10.2 ADC Therapeutics
10.3 BeiGene
10.4 Bristol Myers Squibb
10.5 GlaxoSmithKline
10.6 Innovent
10.7 Merck
10.8 Morphosys
10.9 Ono Pharmaceutical
10.10 Pfizer
10.11 Roche
10.12 Seagen
10.13 Takeda Pharmaceuticals